Part,  Chapter, Paragraph

 1    I,     2.  5    | particularly sustained for the male section of the population, while
 2    I,     2.  7    |               Rural neglect. As the section on the policy tools indicated,
 3   II,     5.  1.  1|         conditions and problems~See section 5.6.~Respiratory diseases
 4   II,     5.  2.  5|           for diabetes mellitus see Section 3.1.5. Annex 1 is also relevant
 5   II,     5.  3.  6|         1999 and 2000-2002. In this Section mainly macro-analysis results
 6   II,     5.  4.  4|           shown in the presentation section indicates an objective difficulty
 7   II,     5.  4.  6|            As shown in the previous section on data presentation, the
 8   II,     5.  4.  6|      process indicators reported in section 5.4.3, which indicate clearly
 9   II,     5.  5.  1|           see also the introductory Section 5.5.1.~ ~Mood and anxiety
10   II,     5.  5.  3|             Gissler M, Wahlbeck K), Section B, p. 257-333, 2007.~htt df~
11   II,     5.  5.  3|      spreadsheets in the data query section. The whole database will
12   II,     5.  5.  3|           Disorder Society-European Section. Part I: early (uncomplicated)
13   II,     5.  6.  3|          described in the following section in terms of definitions,
14   II,     5.  6.  6|           Sambrook) Mosby-Elsevier; Section C, Chapter 1.~Zollman C,
15   II,     5.  8.  2|          The data presented in this section are:~- Data derived from
16   II,     5.  8.  3|     description and analysis~ ~This section addresses incidence, prevalence
17   II,     5.  9. FB|          The data presented in this section are:~- derived from papers
18   II,     5.  9.  2|          The data presented in this section are:~- Data derived from
19   II,     5. 10.  2|          Community legislation (see section 5). EuroPrevall is still
20   II,     5. 10.  3|             intolerant to food (see section 5.10.3.1.) and the number
21   II,     5. 11.  3|         cure.~Other eczemas in this section refer to any eczema that
22   II,     5. 11.  6|      analysis of the available data section is that: i) skin disease
23   II,     6.  3.  3|   transmitted infections (STI)~This section addresses Chlamydia infections
24   II,     6.  3.  3|   Blood-borne viral infections~This section addresses hepatitis B and
25   II,     6.  3.  4|             tract infections~ ~This section addresses influenza, tuberculosis,
26   II,     6.  3.  4|         drug-resistant disease (see section on antimicrobial resistance,
27   II,     7.  4    |           presented in the previous section meet the European standards (
28   II,     8.  2.  1|            rate of prevalence. This section presents an overview of
29   II,     9        |             References cited in the section on congenital anomalies
30   II,     9        |         interactive data) (see also Section 10.2).~ ~Cannabis use. Cannabis
31   II,     9        |         interactive data) (see also Section 10.2).~ ~Sexual health and
32   II,     9.  1.  1|     knowledge see Table 9.1 and the section on maternal health.~ ~HealthCare~ ~
33   II,     9.  1.  1|         Perucci C. Cesarean (1992): section rates in Italy by hospital
34   II,     9.  1.  1|    differences in rates of cesarean section. N Engl J Med 1989;321(4):
35   II,     9.  1.  2|    registers, and the focus of this section. Many registers also include
36   II,     9.  1.  2|             References cited in the section on congenital anomalies
37   II,     9.  1.  2|           anomalies as presented in section 9.1.2.3. Comparisons of
38   II,     9.  2.  1|      constitute a major part of the section of the community for which
39   II,     9.  2.  2|          still focused on the adult section of the population – the
40   II,     9.  2.  3|           indicated earlier in this section, injury is the greatest
41   II,     9.  2.  4|         interactive data) (see also Section 10.2).~ ~Cannabis use. Cannabis
42   II,     9.  2.  4|         interactive data) (see also Section 10.2).~ ~Sexual health and
43   II,     9.  3.  1|             De Smedt, 2004).~ ~This section is also based on the International
44   II,     9.  3.  2|           pain relief and Caesarean section).~ ~Morbidity~ ~Previous
45   II,     9.  3.  2|         tubal ligation or caesarean section) or embolisation (3) blood
46   II,     9.  3.  2|           higher rates of caesarean section for all countries in Europe.
47   II,     9.  3.  2|       parity and previous caesarean section, and also by health system
48   II,     9.  3.  2|         Perucci C. Cesarean (1992): section rates in Italy by hospital
49   II,     9.  3.  2|    differences in rates of cesarean section. N Engl J Med 1989;321(4):
50   II,     9.  5.  2|            and Accidents).~See also section 9.2 for additional data
51  III,    10.  2.  1|            reported in the previous section. Plaque-induced chronic
52  III,    10.  2.  1|     physical activity are quoted in section5.13. Obesity, overweight
53  III,    10.  2.  1|            with in this Report (see section 5.2, 5.3 and 5.4), whereas
54  III,    10.  2.  5| determinants of health. The present section is built on scientific papers
55  III,    10.  2.  5|          and quoted in the relevant section.~ ~The European Early Promotion
56  III,    10.  3.  2|            organic pollutants. This section will address some emerging
57  III,    10.  3.  2|          discussed in the following section in context with human biomonitoring.~ ~
58  III,    10.  4.  2|          hazardous agents (see also Section 4.14.2).~ ~Apart from Regulation
59  III,    10.  4.  2|      general information. A special section is devoted to the bovine
60  III,    10.  4.  2|                   Breast milk~ ~The Section on “Biomonitoring” in Chapter
61  III,    10.  5.  1|            area.~ ~In the following section, the human settlement as
62  III,    10.  5.  2|         accident injuries (see also Section 8.3.1.)~Different than for
63  III,    10.  6.  2|          main data sources for this Section are :~· an independent comprehensive
64  III,    10.  6.  2|            listed in the References Section.~ ~ ~ ~
65   IV,    11.  1.  1|            discussion begins with a section on health systems performance
66   IV,    11.  1.  3|         care. The remainder of this section identifies some of the key
67   IV,    11.  1.  4|    Mossialos and Thomson 2003) (see Section 11.6 on Financing health
68   IV,    11.  1.  4|          and Bakker 2002). See also Section 11.4.2 Public Health Services).~ ~
69   IV,    11.  1.  6|         heavy state regulation (see Section 11.6 Financing Health Care).
70   IV,    11.  2    |            provision~ ~The previous section addressed three key aspects
71   IV,    11.  2    |          care, and efficiency. This section focuses on the delivery
72   IV,    11.  3    |           discussed in the previous section, here we will see the issues
73   IV,    11.  6    |         Financing healthcare~ ~This section reviews the ways in which
74   IV,    11.  6.  2|           and quality of care. This section introduces the key trends
75   IV,    11.  6.  2|        through tax allocations (see section on Social Health Insurance
76   IV,    11.  6.  2|           and Mossialos, 2008) (see Section 11.8.3 on Progressivity).~ ~
77   IV,    11.  6.  3|       resources are collected. This section considers how the funding
78   IV,    11.  6.  4|          Robinson et al, 2005). See section 11.3.4. Technical efficiency
79   IV,    12.  2    |            Policiesprinciple (see Section 12.7.), and is likely to
80   IV,    12.  2    |       health determinant includes a section describing the current status
81   IV,    13.  7.  1|            clusters as described in Section 4 of the Report on “Innovation
82   IV,    13.  8    |           interests of a particular section of society;~They are autonomous